NASDAQ:MEDP - Medpace Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $45.94 +0.05 (+0.11 %) (As of 07/18/2018 12:42 PM ET)Previous Close$45.65Today's Range$45.44 - $46.0452-Week Range$27.07 - $46.18Volume1,264 shsAverage Volume207,084 shsMarket Capitalization$1.58 billionP/E Ratio30.15Dividend YieldN/ABeta0.22 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio. Receive MEDP News and Ratings via Email Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical SymbolNASDAQ:MEDP CUSIPN/A Webwww.medpace.com Phone513-579-9911 Debt Debt-to-Equity Ratio0.41 Current Ratio0.66 Quick Ratio0.66 Price-To-Earnings Trailing P/E Ratio30.15 Forward P/E Ratio24.31 P/E Growth1.68 Sales & Book Value Annual Sales$436.15 million Price / Sales3.74 Cash Flow$2.7103 per share Price / Cash16.95 Book Value$13.40 per share Price / Book3.43 Profitability EPS (Most Recent Fiscal Year)$1.52 Net Income$39.12 million Net Margins10.37% Return on Equity12.50% Return on Assets7.08% Miscellaneous Employees2,500 Outstanding Shares35,530,000Market Cap$1,583.75 Medpace (NASDAQ:MEDP) Frequently Asked Questions What is Medpace's stock symbol? Medpace trades on the NASDAQ under the ticker symbol "MEDP." How were Medpace's earnings last quarter? Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings results on Monday, April, 30th. The company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.17. The firm had revenue of $108.40 million for the quarter, compared to analysts' expectations of $113.12 million. Medpace had a return on equity of 12.50% and a net margin of 10.37%. The company's revenue was up 15.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.34 EPS. View Medpace's Earnings History. When is Medpace's next earnings date? Medpace is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Medpace. What guidance has Medpace issued on next quarter's earnings? Medpace updated its FY18 earnings guidance on Monday, April, 30th. The company provided EPS guidance of $1.87-1.97 for the period, compared to the Thomson Reuters consensus estimate of $1.88. The company issued revenue guidance of $421-435 million, compared to the consensus revenue estimate of $463.04 million. What price target have analysts set for MEDP? 8 analysts have issued 12-month price targets for Medpace's stock. Their predictions range from $35.00 to $42.00. On average, they anticipate Medpace's share price to reach $37.40 in the next twelve months. This suggests that the stock has a possible downside of 18.6%. View Analyst Ratings for Medpace. What is the consensus analysts' recommendation for Medpace? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of Medpace's key competitors? Some companies that are related to Medpace include Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), VIRALYTICS Ltd/S (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA) and Senomyx (SNMX). Who are Medpace's key executives? Medpace's management team includes the folowing people: Dr. August James Troendle, Chairman, Pres & CEO (Age 62)Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 44)Ms. Susan E. Burwig, Exec. VP of Operations (Age 55)Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 49)Mr. Todd Meyers, VP of Bus. Devel. and Marketing When did Medpace IPO? (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. Has Medpace been receiving favorable news coverage? Media coverage about MEDP stock has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medpace earned a media sentiment score of 0.11 on Accern's scale. They also gave news headlines about the company an impact score of 44.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are Medpace's major shareholders? Medpace's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include CINVEN CAPITAL MANAGEMENT (V) GENERAL PARTNER LTD (37.70%) and Fisher Asset Management LLC (0.28%). Company insiders that own Medpace stock include August J Troendle, Medpace Limited Partnership and Susan E Burwig. View Institutional Ownership Trends for Medpace. Which major investors are selling Medpace stock? MEDP stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. View Insider Buying and Selling for Medpace. How do I buy shares of Medpace? Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Medpace's stock price today? One share of MEDP stock can currently be purchased for approximately $45.94. How big of a company is Medpace? Medpace has a market capitalization of $1.58 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe. How can I contact Medpace? Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected] MarketBeat Community Rating for Medpace (NASDAQ MEDP)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 157 (Vote Outperform)Underperform Votes: 145 (Vote Underperform)Total Votes: 302MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?